Gadolinium
- Generic Name
- Gadolinium
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- Gd
- CAS Number
- 7440-54-2
- Unique Ingredient Identifier
- AU0V1LM3JT
- Background
Gadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease. Gadolinium has been investigated for the basic science of CAD, Multiple Sclerosis, and Coronary Artery Disease.
- Associated Conditions
- -
- Associated Therapies
- -
Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- University of Florida
- Registration Number
- NCT02599844
Severe Sepsis in Children - IMPRESS-C
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- University of Florida
- Registration Number
- NCT02598674
- Locations
- 🇺🇸
UF Health, Gainesville, Florida, United States
Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Paul Kim
- Target Recruit Count
- 14
- Registration Number
- NCT02597543
- Locations
- 🇺🇸
UC San Diego, La Jolla, California, United States
Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery
Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- University Hospital, Grenoble
- Target Recruit Count
- 23
- Registration Number
- NCT02530931
- Locations
- 🇫🇷
GrenobleUniversityHospital, Grenoble, France
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT02390635
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Use of Gadolinium in CT Pulmonary Angiography
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT02234375
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
A Feasibility Study to Assess the Use of Gadolinium in Computed Tomography
- First Posted Date
- 2014-06-13
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT02163005
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
ASIS for Enbrel in Plaque Psoriasis
Phase 1
- Conditions
- Interventions
- Drug: Efficacy of Enbrel subcutaneously at Week 12Drug: PASI 75 n(%) subcutaneously at Week 12Drug: Adverse Reactions of Enbrel subcutaneouslyDrug: GadoliniumDrug: PASI 75 n(%) subcutaneously at Week 24Drug: Efficacy of Enbrel subcutaneously at Week 24Drug: Adverse Reactions of Enbrel subdermally at Week 36Drug: Efficacy of Enbrel subcutaneously at Week 36Drug: PASI 75 n(%) subcutaneously at Week 36Drug: Efficacy of Enbrel subdermally at Week 12Drug: PASI 75 n(%) subdermally at Week 12Drug: Efficacy of Enbrel subdermally at Week 24Drug: PASI 75 n(%) subdermally at Week 24Drug: Efficacy of Enbrel subdermally at Week 36Drug: PASI 75 n(%) subdermally at Week 36
- First Posted Date
- 2014-04-11
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- ASIS Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT02112097
- Locations
- 🇺🇸
Automatic Subdermal Injector System, Inc, Westminster, California, United States
ASIS for Botox in Upper Limb Spasticity
Phase 1
- Conditions
- Interventions
- Drug: GadoliniumDrug: Efficacy of Botox intramuscularly at Week 6Drug: Adverse Reactions of Botox intramuscularlyDrug: Efficacy of Botox intramuscularly at Week 12,Drug: Adverse Reactions of Botox subdermallyDrug: Efficacy of Botox intramuscularly at Week 18Drug: Efficacy of Botox intramuscularly at Week 24Drug: Efficacy of Botox intramuscularly at Week 30Drug: Efficacy of Botox subdermally at Week 6Drug: Efficacy of Botox subdermally at Week 12Drug: Efficacy of Botox subdermally at Week 18Drug: Efficacy of Botox subdermally at Week 24Drug: Efficacy of Botox subdermally at Week 30
- First Posted Date
- 2014-02-28
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- li nguyen
- Target Recruit Count
- 60
- Registration Number
- NCT02074150
- Locations
- 🇺🇸
Automatic Subdermal Injector System, Inc, Westminster, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath